Startup Funding

AstraZeneca Pharma India gets CDSCO nod to import and market datverzo breast cancer drug

Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Shares of Astrazeneca Pharma India Ltd ended at ₹8,984.50, down by ₹32.00, or 0.35%, on the BSE.

Startup Funding

Coursera to acquire Udemy in $2.5 billion all-stock deal

Under the terms of the deal, Udemy shareholders will receive 0.8 shares of Coursera for every share held. The deal implies an acquisition price of approximately $6.35 per Udemy share — a 26% premium over the 30-day average closing price

Startup Funding

India-Oman trade deal: How the CEPA will anchor India’s expanding Gulf strategy; strengthen strategic and investment footprint

India and Oman are set to sign a Comprehensive Economic Partnership Agreement on December 18, aiming to deepen economic ties and expand India's trade and strategic footprint in the Gulf. The pact will cover goods, services, and investment, reducing tariffs and facilitating business, while also carrying significant geopolitical weight.

Startup Funding

UGRO Capital's panel approves ₹500-crore NCD issue via private placement

The Investment and Borrowing Committee cleared the base issue size of up to ₹200 crore, with an option to retain oversubscription of up to ₹300 crore under a green shoe option. Shares of Ugro Capital Ltd ended at ₹171.20, down by ₹0.22, or 0.13%, on the BSE today, December 17.

Startup Funding

US stocks inch up as investors eye monetary policy outlook

Wall Street indexes traded higher in volatile sessions as investors sought interest rate outlook clues. Oracle shares dipped amid funding concerns for its data center plans, impacting the tech sector's AI ambitions. Energy stocks rebounded, while Netflix saw gains following reports of a potential OpenAI investment.